StockData
Moderna, Inc. logo

Moderna, Inc. (MRNA) stock

MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30537% above fair value
$206.80−8.47 (-3.93%)

Close on Nov 17, 2026Market cap $82.56BP/E –Yield –

Moderna price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Moderna's price to book ratio was 14.7× on Nov 11, 2026, against 1.1× a year earlier. Over the last 5 years it ranged from 1.0× to 14.7×, with a median of 2.6×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202614.7×+13.4
2025Dec 31, 20251.2×−0.1
2024Dec 31, 20241.3×−1.5
2023Dec 29, 20232.8×−1.0
2022Dec 30, 20223.9×−6.3
2021Dec 31, 202110.2×−4.8
2020Dec 31, 202015.0×+9.8
2019Dec 31, 20195.2×–

More Moderna figures

See a number that looks wrong?